CHEK2 and breast cancer: From a clinical perspective, the risk of breast cancer conferred by some pathogenic sequence variants in CHEK2 may be great enough to be of use in a clinical cancer genetics setting, and we note that the technical capability of offering a multigene breast cancer susceptibility testing panel at relatively low per gene laboratory cost is in place.